Literature DB >> 10344642

Myocardial parasite persistence in chronic chagasic patients.

N Añez1, H Carrasco, H Parada, G Crisante, A Rojas, C Fuenmayor, N Gonzalez, G Percoco, R Borges, P Guevara, J L Ramirez.   

Abstract

The persistence of Trypanosoma cruzi tissue forms was detected in the myocardium of seropositive individuals clinically diagnosed as chronic chagasic patients following endomyocardial biopsies (EMBs) processed by immunohistochemical (peroxidase-anti-peroxidase [PAP] staining) and molecular (polymerase chain reaction [PCR]) techniques. An indirect immunofluorescent technique revealed antigenic deposits in the cardiac tissue in 24 (88.9%) of 27 patients. Persistent T. cruzi amastigotes were detected by PAP staining in the myocardium of 22 (84.6%) of 26 patients. This finding was confirmed with a PCR assay specific for T. cruzi in 21 (91.3%) of 23 biopsy specimens from the same patients. Statistical analysis revealed substantial agreement between PCR and PAP techniques (k = 0.68) and the PCR and any serologic test (k = 0.77). The histopathologic study of EMB specimens from these patients revealed necrosis, inflammatory infiltrates, and fibrosis, and made it possible to detect heart abnormalities not detected by electrocardiogram and/or cineventriculogram. These indications of myocarditis were supported by the detection of T. cruzi amastigotes by the PAP technique or its genome by PCR. They suggest that although the number of parasites is low in patients with chronic Chagas' disease, their potential for heart damage may be comparable with those present during the acute phase. The urgent necessity for testing new drugs with long-term effects on T. cruzi is discussed in the context of the present results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344642     DOI: 10.4269/ajtmh.1999.60.726

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 2.  Role of autoantibodies in the physiopathology of Chagas' disease.

Authors:  Emiliano Horacio Medei; José Hamilton Matheus Nascimento; Roberto Coury Pedrosa; Antônio Carlos Campos de Carvalho
Journal:  Arq Bras Cardiol       Date:  2008-10       Impact factor: 2.000

3.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Montserrat Gállego; Paulo Luis López-Chejade; Julio A Urbina; Joaquim Gascón
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 4.  Diagnosis and Management of Chagas Cardiomyopathy in the United States.

Authors:  Lillian Benck; Evan Kransdorf; Jignesh Patel
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

5.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.

Authors:  A L Basquiera; A Sembaj; A M Aguerri; M Omelianiuk; S Guzmán; J Moreno Barral; T F Caeiro; R J Madoery; O A Salomone
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

8.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 9.  Epidemiology of Chagas disease in Europe: many calculations, little knowledge.

Authors:  Jörn Strasen; Tatjana Williams; Georg Ertl; Thomas Zoller; August Stich; Oliver Ritter
Journal:  Clin Res Cardiol       Date:  2013-08-29       Impact factor: 5.460

10.  Bioluminescent imaging of Trypanosoma cruzi infection.

Authors:  Kenneth V Hyland; Sofya H Asfaw; Cheryl L Olson; Melvin D Daniels; David M Engman
Journal:  Int J Parasitol       Date:  2008-04-25       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.